NEURO61

Session information

[held on paper]English Poster Session

[Pe-02] English Poster Session 02
Dementia (biomarker, test method 2)

Takenobu Murakami1,2, Mitsunari Abe3, Amanda Tiksnadi2, Ayaka Nemoto4, Hitoshi Kubo4, Naoto Kobayashi5, Hiroshi Ito4,6, Yasuhiro Hashimoto7, Yoshikazu Ugawa2,8 (1.Neurology, Tottori Prefectural Kousei Hospital, Japan, 2.Neurology, Fukushima Medical University, Japan, 3.Center for Neurological Disorders, Fukushima Medical University, 4.Advanced Clinical Research Center, Fukushima Medical University, 5.Azuma Street Clinic, 6.Radiology, Fukushima Medical University, 7.Biochemistry, Fukushima Medical University, 8.Neuro-regeneration, Fukushima Medical University)

Tatsuhiro Terada1, Tomokazu Obi1, Tomoyasu Bunai2, Takashi Matsudaira1,2, Etsuji Yoshikawa3, Ichiro Ando3, Masami Futatsubashi3, Hideo Tsukada3, Norihiko Kawaguchi1, Yasukiyo Araki1, Yasuomi Ouchi2 (1.Department of Neurology, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Japan, 2.Department of Biofunctional Imaging, Preeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine, 3.Central Research Laboratory, Hamamatsu Photonics KK)

Makiko Shinomoto1, Takashi Kasai1, Harutsugu Takebe2, Fukiko Kitani-morii1, Takuma Ohmichi1, Toshiki Mizuno1, Takahiko Tokuda1,3 (1.Kyoto Prefectural University of Medicine, Department of Neurology, Japan, 2.Kyoto Prefectural University of Medicine, Department for Medical Innovation and Translational Medical Science, 3.Kyoto Prefectural University of Medicine, Department of Molecular Pathobiology of Brain Disease)

Taro Yasumoto1,2,3, Yusaku Takamura5, Mayumi Tsuji2,3, Takahiro Nakayama6, Keiko Imamura7, Haruhisa Inoue7, Shiro Nakamura4, Tomio Inoue4, Atsushi Kimura1,2,3, Satoshi Yano1, Hisao Nishijo5, Yuji Kiuchi2,3, David B Teplow8, Kenjiro Ono1 (1.Department of Neurology, School of Medicine, Showa University, Tokyo, Japan, 2.Pharmacological Research Center, Showa University, Tokyo, Japan, 3.Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan, 4.Department of Oral Physiology, School of Dentistry, Showa University, Tokyo, Japan, 5.System Emotional Science, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, 6.World Premier International Research Center Initiative (WPI)-Nano Life Science Institute, Kanazawa University, Kanazawa, Japan, 7.Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan, 8.University of California-Los Angeles, LA, USA)

Kentaro Hirao1, Fumio Yamashita2, Akito Tsugawa1, Haime Rieko1, Tomohiko Sato1, Misa Okita1, Soichiro Shimizu1, Hidekazu Kanetaka1, Takahiko Umahara1, Hirofumi Sakurai1, Haruo Hanyu1 (1.Department of Geriatric medicine, Tokyo Medical University Hospital, Tokyo, Japan, 2.Department of Ultrahigh Field MRI, Institute for Biomedical Sciences, Iwate Medical University, Iwate, Japan)

Gregory Klein1, Paul Delmar2, Geoffrey A. Kerchner2, Carsten Hofmann2, Danielle Abi-saab2, Smiljana Ristic3, Andrew Davis3, Nicola Voyle3, Hironori Tatsuda4, Monika Baudler2, Paulo Fontoura2, Rachelle Doody5 (1.Roche Pharma Research and Early Development, Switzerland, 2.Roche/Genentech Product Development, 3.Roche Products Ltd., 4.Chugai Pharmaceutical Co., Ltd., 5.Genentech, Inc.)